Quality of life and symptoms in patients with myelofibrosis during the treatment: Data of clinical practice
The aim of the study was to evaluate the quality of life (QoL) and symptoms in patients with myelofibrosis (MF). 93 patients with Mf who participated in the multicenter observational study "Quality of life and symptoms in myelofibrosis: validation of the symptom assessment tool for patients with myelofibrosis" (2014-2015) were enrolled in the analysis. 62 patients received best available treatment (BAT) and 31 patients received ruxolitinib. All the patients filled out the SF-36, CSP-Myelofibrosis Module and Patient Global Impression of Change (PGIC) tools. In the real-world study in MF patients QoL was demonstrated to be significantly worse than in healthy controls; more than one third of patients had significant or severe QoL impairment. Patients treated with ruxolitinib had better QoL and lower symptom severity as compared to BAT patients. Decline of activity appeared to be the major symptom which significantly reduced QoL in MF patients. QoL and symptom data in MF patients during treatment in a real world setting may be a solid supplement to clinical variables and may contribute to better disease control in accordance with the principles of risk-adaptive therapy.
About the authorsIonova Tatyana I.
Mesa R.A., Kantarjian H., Tefferi A., Dueck A., Levy R., Vaddi K., et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011; 117(21): 4869-77. doi: 10.1002/cncr.26129.
Harrison C.N., Mesa R.A., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Knoops L., et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br. J. Haematol. 2013; 162(2): 229-39. doi: 10.1111/bjh.12375.
Kiladjian J.J., Gisslinger H., Passamonti F., Niederwieser D., Mendelson E., Sirulnik L.A., et al. Health-related quality of life and symptom burden in patients with myelofibrosis in the COMFORT-II study. J. Clin. Oncol. 2012; 30 (Suppl): Abstr. 6626.
Vargas-Viveros P., Hurtado-Monroy R., Candelaria-Hernández M. Significant Improvement in Quality of Life (QoL) in Patients with Chronic Myeloproliferative Neoplasms (CMPN) and Myelofibrosis Treated with JAK-1 and JAK-2 Inhibitor Ruxolitinib. Clin. Lymph. Myeloma Leuk. 2014; 14 (Suppl): S155-6.
Common Terminology Criteria for Adverse Evens (CTCAE 3) Version 3.0 12.12.2003. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
Hays R.D., Sherbourne C.D., Mazel R.M. User’s Manual for Medical Outcomes Study (MOS) Core measures of health-related quality of life. RAND Corporation, MR-162-RC. Available at: http://www.rand.org.
Novik A.A., Ionova T.I., Kishtovich A.V., Tsepkova A.A., Mylnikov S.V. Stratification of patients using QoL parametrs by the method of integral profiles. Quality Life Res. 2003; 12(7): 770.
Hurst H., Bolton J. Assessing the clinical significance of changes cores recorded on subjective outcome measures. J. Manipulative Physiol. Ther. 2004; 27(1): 26-35.
Mesa R.A., Harrison C.N., Cervantes F., Dean J.P., Wang L., Granston T., et al. Relationship between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and efficacy in patients with myelofibrosis in the phase III persist-1 trial of Pacritinib vs. Best Available Therapy (BAT). Blood. 2015; 126(23): Abstr. 1609. http://www.bloodjournal.org/content/126/23/1609?sso-checked=true
Fauble V., Emanuel R.M., Geyer H.L., Dueck A.C., Kroeger N., Scott B.L., et al. Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Observational Study of quality of life and symptomatic response in myelofibrosis patients receiving undergoing treatment with conventional therapy, the measures trial and allogeneic stem cell transplant, the symptoms trial. Blood. 2013; 122 (21): 4090. https://ash.confex.com/ash/2013/webprogram/Paper65062.html
Davis K.L., Côté I., Kaye J.A., Mendelson E., Gao H., Ronco J.P. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with Ruxolitinib. Adv. Hematol. 2015; 2015. Article ID 848473. doi:10.1155/2015/848473.http://dx.doi.org/10.1155/2015/848473
Emanuel R.M., Geyer H.L., Mesa R.A. Ruxolitinib as an emerging treatment in myelofibrosis. Blood Lymph. Cancer: Targets Ther. 2013; 3: 11-8. http://dx.doi.org/10.2147/BLCTT.S24926
Mesa R.A., Schwager S., Radia D., Cheville A., Hussein K., Niblack J., et al. The Myeloﬁbrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myeloﬁbrosis. Leuk. Res. 2009; 33(9): 1199-203. doi: 10.1016/j.leukres.2009.01.035.
Mitra D., Kaye J.A., Piecoro L.T., Brown J., Reith K., Mughal T.I., Sarlis N.J. Symptom burden and splenomegaly in patients with myeloﬁbrosis in the United States: a retrospective medical record review. Cancer Med. 2013; 2(6): 889-98. doi: 10.1002/cam4.136.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.